5,512 Shares in Inhibrx, Inc. (NASDAQ:INBX) Acquired by E Fund Management Co. Ltd.

E Fund Management Co. Ltd. acquired a new stake in Inhibrx, Inc. (NASDAQ:INBX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 5,512 shares of the company’s stock, valued at approximately $209,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Eventide Asset Management LLC purchased a new stake in Inhibrx during the 3rd quarter valued at about $7,964,000. RA Capital Management L.P. grew its holdings in Inhibrx by 22.6% in the 3rd quarter. RA Capital Management L.P. now owns 4,724,207 shares of the company’s stock valued at $86,689,000 after buying an additional 870,340 shares in the last quarter. Citigroup Inc. increased its stake in shares of Inhibrx by 3.4% in the 3rd quarter. Citigroup Inc. now owns 49,244 shares of the company’s stock worth $904,000 after acquiring an additional 1,611 shares during the last quarter. Wellington Management Group LLP raised its holdings in shares of Inhibrx by 24.4% during the 3rd quarter. Wellington Management Group LLP now owns 174,899 shares of the company’s stock worth $3,209,000 after acquiring an additional 34,310 shares during the period. Finally, Swiss National Bank grew its holdings in shares of Inhibrx by 2.1% in the third quarter. Swiss National Bank now owns 57,600 shares of the company’s stock valued at $1,057,000 after purchasing an additional 1,200 shares during the period. Hedge funds and other institutional investors own 82.46% of the company’s stock.

Analyst Upgrades and Downgrades

INBX has been the topic of several recent analyst reports. JMP Securities reiterated a “market perform” rating on shares of Inhibrx in a report on Tuesday, January 23rd. Lifesci Capital lowered Inhibrx from an “outperform” rating to a “market perform” rating in a research report on Tuesday, January 23rd.

Inhibrx Trading Up 0.7 %

Shares of INBX stock opened at $34.69 on Friday. The company has a 50-day moving average of $34.83 and a two-hundred day moving average of $31.31. The firm has a market cap of $1.81 billion, a PE ratio of -6.90 and a beta of 2.87. Inhibrx, Inc. has a 1-year low of $14.31 and a 1-year high of $39.79. The company has a debt-to-equity ratio of 4.78, a current ratio of 5.24 and a quick ratio of 5.25.

Inhibrx (NASDAQ:INBX) last announced its earnings results on Wednesday, February 28th. The company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.66). Inhibrx had a negative net margin of 13,408.95% and a negative return on equity of 590.78%. The firm had revenue of $1.63 million during the quarter, compared to analysts’ expectations of $0.10 million. On average, analysts predict that Inhibrx, Inc. will post -4.34 EPS for the current year.

Inhibrx Profile

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.